SIP
HZNP

Stoneridge Investment Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Stoneridge Investment Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-14,946
Closed -$190K – 283
2017
Q3 		$190K Sell
14,946
-5,002
-25% -$63.6K 0.03% 221
2017
Q2 		$237K Buy
+19,948
New +$248K 0.04% 216
2013
Q3 		– Sell
-35,070
Closed -$86K – 241
2013
Q2 		$86K Buy
+35,070
New +$84.1K 0.02% 198

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stoneridge Investment Partners's HZNP Position: Q4 2017 in Review

Stoneridge Investment Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2017, closing a stake of 14,946 shares — an estimated $190K sold.

Stoneridge Investment Partners first reported a position in HZNP in Q2 2013 and held it in 3 quarters. The position peaked at $237K in Q2 2017. 183 funds tracked by Wall St. Rank hold HZNP as of Q4 2017.

  • Stoneridge Investment Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 14,946 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2017, an estimated $190K.
  • Stoneridge Investment Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 3 quarters.
  • Stoneridge Investment Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $237K in Q2 2017.
  • 183 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2017.

Based on Stoneridge Investment Partners's 13F filing for Q4 2017, filed 5 Feb 2018.